Nelfinavir mesylate

An HIV protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Nelfinavir Mesylate is the mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2 (NCIt).

Nelfinavir on DrugBank
Nelfinavir mesylate on PubChem
Nelfinavir on Wikipedia

Marketed as



Structure image - Nelfinavir mesylate


Supporting references

Link Tested on Impact factor Notes Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Preprint In silico
in silico Feb/02/2020
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19
Preprint Screening
VERO cells Mar/19/2020
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
VERO cells Apr/24/2020
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
VERO E6 cell cultures

better in combination with cepharanthine

Antiviral options against SARS-CoV-2 infection
Preprint Screening
VERO E6 cell cultures

synergistic effect in combination with host-directed drugs, such as salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro
VERO E6 cell cultures

better than lopinavir or tipranavir

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Preprint In vitro Screening
HeLa-ACE2 cells Jun/16/2020
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Preprint Screening
human A549-ACE2 cells Jun/23/2020
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
in silico 3.31

In silico screening of potential SARS-CoV-2 3C-like protease inhibitors.

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
3CLpro PapainLpro Enzyme assay Animal model In vitro In silico
in silico; in vitro enzyme assay; Vero E6 cells; golden Syrian hamsters; SARS-CoV-2 clinical isolate hCoV-19/Taiwan/4/2020 9.41

Inhibited SARS-CoV-2 infection in Vero E6 cells (selectivity index of ca. 3.7). Oral administration preceding viral challenge significantly decreased lung viral loads in golden Syrian hamsters. The drug inhibited SARS-CoV-2 3C-like protease in vitro.


AI-suggested references